GlobalData on MSN
FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease
Novartis intends to submit ianalumab for regulatory approval globally in early 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback